The Hidden Danger of IgAN: Pathogenesis and Unmet Needs
Jonathan Barratt, MD, PhD
Unmasking IgAN: Achieving Earlier Diagnosis
An De Vriese, MD, PhD
Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal
Mechanisms Matter! Optimizing Proteinuria Reduction In IgAN
Chee Kay Cheung, MBChB, MRCP, PhD
Jörg Latus, MD
Translating Evidence into IgAN Care
The Future of IgAN Care
The Evolving Role of Biomarkers in IgAN
CKD-aP Uncovered Prevalence & Pathophysiology
Steven Fishbane, MD
Nancy Helou, PhD
Spotlight on Assessment: Tools That Capture CKD-aP
Federico Alberici, MD, PhD
Anastasia Liossatou, PhD, RN
When Itching Hurts: Quality of Life Disruption in CKD-aP
Optimizing Outcomes in Patients with FSGS: A Case-Based Approach in the New Era of Targeted Therapy
Sayna Norouzi, MD
Engaging Adult Patients With C3GN: Shared Decision-Making at the Crossroads of Complement-Targeted Therapy
Turning the Double Play – Comprehensive Secondary Prevention
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Leadoff Hitter – Spotting High-Risk Players
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Richard Lafayette, MD, FACP
Ankana Daga, MD